We are live on ! Find out more
ASBP

Aspire Biopharma
ASBP

23 hedge funds and large institutions have $646K invested in Aspire Biopharma in 2025 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 3

64% more funds holding

Funds holding: 14 → 23 (+9)

19% more capital invested

Capital invested by funds: $545K → $646K (+$101K)

0% more ownership

Funds ownership: 0% → 0.01% (+0%)

0% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 3

Holders
23
Holders Change
+9
Holders Change %
+64.29%
% of All Funds
0.3%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.01%
New
12
Increased
3
Reduced
3
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$179K
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$104K
3
AC
Antara Capital
New York
+$84.6K
4
CA
Crewe Advisors
Utah
+$78.1K
5
RA
Resolute Advisors
California
+$34.5K

Top Sellers

Rank Fund Capital Flow
1
PA
Procyon Advisors
Connecticut
-$73.1K
2
Jane Street
Jane Street
New York
-$51.6K
3
PC
Periscope Capital
Ontario, Canada
-$10.5K
4
Goldman Sachs
Goldman Sachs
New York
-$5.03K
5
SRL
Scientech Research LLC
New Jersey
-$4.44K
Name Holding Trade Value Shares
Change 		Change in
Stake
CA
1
Crewe Advisors
Utah
$168K +$78.1K +156 +30%
PA
2
Procyon Advisors
Connecticut
$97.4K -$73.1K -146 -27%
Vanguard Group
3
Vanguard Group
Pennsylvania
$88.3K +$179K +357 New
OAS
4
Optivise Advisory Services
Tennessee
$54.3K +$12K +24 +12%
Geode Capital Management
5
Geode Capital Management
Massachusetts
$51.5K +$104K +208 New
AC
6
Antara Capital
New York
$41.8K +$84.6K +169 New
VAS
7
VR Advisory Services
Cayman Islands
$20.1K – – –
RA
8
Resolute Advisors
California
$17.1K +$34.5K +69 New
TSW
9
Three Seasons Wealth
Utah
$15.4K – – –
PSAMP
10
P. Schoenfeld Asset Management (PSAM)
New York
$12.1K +$24.5K +49 New
AW
11
Avion Wealth
Texas
$11K +$22.5K +45 New
PC
12
Periscope Capital
Ontario, Canada
$10.3K -$10.5K -21 -33%
CIBC Private Wealth Group
13
CIBC Private Wealth Group
Georgia
$10.1K +$17.5K +35 +583%
VWM
14
Valley Wealth Managers
New Jersey
$8.24K – – –
PTP
15
Platform Technology Partners
New York
$7.75K – – –
CA
16
Crossingbridge Advisors
New York
$7.42K +$10K +20 New
TRCT
17
Tower Research Capital (TRC)
New York
$6.41K +$13K +26 New
Jane Street
18
Jane Street
New York
$6.03K -$51.6K -103 -81%
XT
19
XTX Topco
Cayman Islands
$5.74K +$11.5K +23 New
Focus Partners Wealth
20
Focus Partners Wealth
Massachusetts
$2.58K +$5.01K +10 New
ACM
21
Allred Capital Management
Texas
$2.3K – – –
UBS Group
22
UBS Group
Switzerland
$1.58K +$3K +6 New
SWA
23
SOA Wealth Advisors
New York
$602 +$1K +2 New
Bank of America
24
Bank of America
North Carolina
$52 – – –
Osaic Holdings
25
Osaic Holdings
Arizona
$20 – – –
1
2

ASBP Hedge Fund Activity: Q3 2025 in Review

23 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Aspire Biopharma (ASBP) for Q3 2025, worth a combined $646K — up 19% from $545K a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new ASBP positions and 3 closed out — a net gain of 9 holders — while 3 added to existing stakes and 3 trimmed.

The largest buyer was Vanguard Group, opening a new position worth an estimated $179K. The largest seller was Procyon Advisors, cutting an estimated $73.1K.

  • 23 institutional investors held Aspire Biopharma (ASBP) as of Q3 2025, up from 14 in Q2 2025.
  • Funds reported $646K of Aspire Biopharma stock for Q3 2025, up 19% quarter-over-quarter.
  • 12 funds opened new Aspire Biopharma positions in Q3 2025 and 3 closed out, a net change of +9 holders.
  • The largest Aspire Biopharma buyer in Q3 2025 was Vanguard Group, an estimated $179K added.
  • The largest Aspire Biopharma seller in Q3 2025 was Procyon Advisors, an estimated $73.1K sold.

Based on aggregated 13F filings for Q3 2025.